[Federal Register Volume 60, Number 143 (Wednesday, July 26, 1995)]
[Notices]
[Page 38353]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-18348]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made final findings of scientific misconduct in the following
case:
Jose R. Sotolongo, Jr., M.D., Mount Sinai Medical Center: On July
3, 1995, ORI found that Jose R. Sotolongo, Jr., M.D., formerly of Mount
Sinai Medical Center in New York, committed scientific misconduct by
falsifying research involving guanabenz treatment of spinal cord
injured cats presented in a Public Health Service (PHS) grant
application.
Dr. Sotolongo has entered into a Voluntary Exclusion Agreement with
ORI in which he has accepted ORI's finding and has agreed to exclude
himself voluntarily, for the three (3) year period beginning July 3,
1995, from:
(1) Applying for or receiving any Federal grant or contract funds;
and,
(2) Serving in any advisory capacity to the PHS, including but not
limited to service on any PHS advisory committee, board, and/or peer
review committee, or as a consultant.
The above voluntary exclusion, however, shall not apply to Dr.
Sotolongo's future training or practice of clinical medicine as a
licensed practitioner unless that practice involves research or
research training.
No scientific publications were required to be corrected as part of
this Agreement.
FOR FURTHER INFORMATION CONTACT: Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-18348 Filed 7-25-95; 8:45 am]
BILLING CODE 4110-60-P
